Surrozen, Inc./DE (SRZN) stock

SRZNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 5/30

$31.61−0.06 (-0.19%)

Close on Nov 13, 2026Market cap $371.53MP/E –Yield –

Surrozen EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Surrozen has not reported this figure in its SEC filings, or the share price needed to calculate it is not available yet.

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SRZN.

Revenue growth-8.8% · median -9.8%

Operating margin-385.3% · median -357.5%

Net margin-2885.3% · median -356.9%

Advertisement
300 × 250

See a number that looks wrong?